vs
Side-by-side financial comparison of Angel Oak Mortgage REIT, Inc. (AOMR) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
Spero Therapeutics, Inc. is the larger business by last-quarter revenue ($12.6M vs $10.9M, roughly 1.2× Angel Oak Mortgage REIT, Inc.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs 103.9%, a 146.8% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs 10.4%). Over the past eight quarters, Spero Therapeutics, Inc.'s revenue compounded faster (847.7% CAGR vs 12.7%).
Angel Oak Mortgage REIT, Inc. is a U.S.-based real estate investment trust focused on investing in residential mortgage assets, including non-agency mortgage-backed securities, residential mortgage loans, and credit-linked real estate instruments. It serves U.S. institutional and retail investors, targeting competitive risk-adjusted returns through regular income and long-term capital growth.
AOMR vs SPRO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.9M | $12.6M |
| Net Profit | $11.3M | $31.5M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | 103.9% | 250.7% |
| Revenue YoY | 10.4% | 24080.8% |
| Net Profit YoY | 175.2% | 250.9% |
| EPS (diluted) | $0.44 | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $10.9M | $12.6M | ||
| Q3 25 | $10.2M | $0 | ||
| Q2 25 | $9.9M | $0 | ||
| Q1 25 | $10.1M | $12.0K | ||
| Q4 24 | $9.9M | $52.0K | ||
| Q3 24 | $9.0M | $65.0K | ||
| Q2 24 | $9.5M | $114.0K | ||
| Q1 24 | $8.6M | $140.0K |
| Q4 25 | $11.3M | $31.5M | ||
| Q3 25 | $11.4M | $-7.4M | ||
| Q2 25 | $767.0K | $-1.7M | ||
| Q1 25 | $20.5M | $-13.9M | ||
| Q4 24 | $-15.1M | — | ||
| Q3 24 | $31.2M | $-17.1M | ||
| Q2 24 | $-273.0K | $-17.9M | ||
| Q1 24 | $12.9M | $-12.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 7.7% | — | ||
| Q1 25 | — | -122758.3% | ||
| Q4 24 | -152.6% | — | ||
| Q3 24 | — | -28604.6% | ||
| Q2 24 | -1.4% | -16720.2% | ||
| Q1 24 | — | -9987.1% |
| Q4 25 | 103.9% | 250.7% | ||
| Q3 25 | 112.1% | — | ||
| Q2 25 | 7.7% | — | ||
| Q1 25 | 203.5% | -115550.0% | ||
| Q4 24 | -152.6% | — | ||
| Q3 24 | 345.9% | -26380.0% | ||
| Q2 24 | -2.9% | -15668.4% | ||
| Q1 24 | 150.1% | -9049.3% |
| Q4 25 | $0.44 | $0.56 | ||
| Q3 25 | $0.46 | $-0.13 | ||
| Q2 25 | $0.03 | $-0.03 | ||
| Q1 25 | $0.87 | $-0.25 | ||
| Q4 24 | $-0.62 | — | ||
| Q3 24 | $1.29 | $-0.32 | ||
| Q2 24 | $-0.01 | $-0.33 | ||
| Q1 24 | $0.51 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $41.6M | $40.3M |
| Total DebtLower is stronger | $2.3B | — |
| Stockholders' EquityBook value | $267.5M | $59.0M |
| Total Assets | $2.7B | $68.9M |
| Debt / EquityLower = less leverage | 8.51× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $41.6M | $40.3M | ||
| Q3 25 | $51.6M | $48.6M | ||
| Q2 25 | $40.5M | $31.2M | ||
| Q1 25 | $38.7M | $48.9M | ||
| Q4 24 | $40.8M | $52.9M | ||
| Q3 24 | $42.1M | $76.3M | ||
| Q2 24 | $44.0M | $63.5M | ||
| Q1 24 | $39.4M | $82.3M |
| Q4 25 | $2.3B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $267.5M | $59.0M | ||
| Q3 25 | $264.2M | $26.5M | ||
| Q2 25 | $246.4M | $32.8M | ||
| Q1 25 | $251.5M | $33.8M | ||
| Q4 24 | $239.0M | $46.1M | ||
| Q3 24 | $265.1M | $65.5M | ||
| Q2 24 | $255.8M | $80.5M | ||
| Q1 24 | $263.3M | $96.2M |
| Q4 25 | $2.7B | $68.9M | ||
| Q3 25 | $2.6B | $54.2M | ||
| Q2 25 | $2.6B | $62.1M | ||
| Q1 25 | $2.7B | $77.7M | ||
| Q4 24 | $2.3B | $110.5M | ||
| Q3 24 | $2.3B | $135.2M | ||
| Q2 24 | $2.1B | $149.9M | ||
| Q1 24 | $2.3B | $167.7M |
| Q4 25 | 8.51× | — | ||
| Q3 25 | 8.37× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 7.62× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-407.0M | $-8.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -35.96× | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-407.0M | $-8.4M | ||
| Q3 25 | $-173.4M | $17.4M | ||
| Q2 25 | $20.6M | $-17.7M | ||
| Q1 25 | $-201.7M | $-4.0M | ||
| Q4 24 | $-221.5M | $-23.4M | ||
| Q3 24 | $-212.4M | $12.8M | ||
| Q2 24 | $-24.2M | $-18.7M | ||
| Q1 24 | $40.2M | $5.9M |
| Q4 25 | -35.96× | -0.26× | ||
| Q3 25 | -15.19× | — | ||
| Q2 25 | 26.92× | — | ||
| Q1 25 | -9.83× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -6.81× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 3.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AOMR
| Nonrelated Party | $6.4M | 59% |
| Other | $4.5M | 41% |
SPRO
Segment breakdown not available.
